The Role of 18F-FDG PET/CT in Guiding Precision Medicine for Invasive Bladder Carcinoma.

Girard, Antoine; Vila Reyes, Helena; Shaish, Hiram; Grellier, Jean-François; Dercle, Laurent; Salaün, Pierre-Yves; Delcroix, Olivier; Rouanne, Mathieu

Girard, Antoine; Vila Reyes, Helena; Shaish, Hiram; Grellier, Jean-François; Dercle, Laurent; Salaün, Pierre-Yves; Delcroix, Olivier; Rouanne, Mathieu.

Afiliação

Girard A; Department of Nuclear Medicine, Centre Eugène Marquis, Université Rennes 1, Rennes, France.
Vila Reyes H; Department of Urology, Columbia University Irving Medical Center - New York Presbyterian Hospital, New York, NY, United States.
Shaish H; Department of Radiology, Columbia University Medical Center, New York, NY, United States.
Grellier JF; Centre Cardiologique du Nord, Nuclear Medicine, Saint-Denis, France.
Dercle L; Department of Radiology, New York Presbyterian Hospital - Columbia University Medical Center, New York, NY, United States.
Salaün PY; Department of Nuclear Medicine, Centre Hospitalier Régional Universitaire de Brest, Brest cedex, France.
Delcroix O; Department of Nuclear Medicine, Centre Hospitalier Régional Universitaire de Brest, Brest cedex, France.
Rouanne M; Department of Urology, Hôpital Foch, Université Versailles-Saint-Quentin-en-Yvelines, Université Paris-Saclay, Suresnes, France.

Front Oncol ; 10: 565086, 2020.

Article em En | MEDLINE | ID: mdl-33117695

Palavras-chave

PET Positron Emission Tomography; bladder cancer; immunotherapy; muscle invasive bladder cancer; staging

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Front Oncol Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google